Clinical Trial

PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms

Study acronym: PIONEERS
Recruiting
View on ClinicalTrials.gov →
Summary
In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-04-30
notable Primary completion moved earlier: 2030-08-31 -> 2030-04-15 2026-04-30
minor Completion moved earlier: 2030-12-30 -> 2030-05-15 2026-04-30
Trial Details
NCT Number NCT07099976
Lead Sponsor Jeffrey Pernica
Conditions Community-Acquired Pneumonia (CAP), Pneumonia
Enrollment 698 participants
Start Date 2026-04-15
Primary Completion 2030-04-15 (estimated)
Study Completion 2030-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-29